Sundial Growers Inc
NASDAQ:SNDL

Watchlist Manager
Sundial Growers Inc Logo
Sundial Growers Inc
NASDAQ:SNDL
Watchlist
Price: 1.87 USD 5.06%
Market Cap: 481.2m USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SNDL stock under the Base Case scenario is 2.29 USD. Compared to the current market price of 1.87 USD, Sundial Growers Inc is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SNDL Relative Value
Base Case
2.29 USD
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
69
vs Industry
79
Median 3Y
0.7
Median 5Y
0.9
Industry
2.6
Forward
0.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-5.8
Industry
21.8
Forward
-85
More Details
11.1
P/OCF
P/OCF
Price to OCF
11.1
vs History
23
vs Industry
30
Median 3Y
7.6
Median 5Y
-9.7
Industry
16.5
More Details
63
P/FCFE
P/FCFE
Price to FCFE
63
vs History
14
vs Industry
Median 3Y
-7.5
Median 5Y
-8
Industry
22.8
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
46
vs Industry
75
Median 3Y
0.5
Median 5Y
0.6
Industry
2.3
More Details
0.6
EV/S
EV/S
Enterprise Value to Sales
0.6
vs History
63
vs Industry
85
Median 3Y
0.6
Median 5Y
0.8
Industry
2.8
Forward
0.6
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
76
vs Industry
72
Median 3Y
2.4
Median 5Y
3.2
Industry
5.4
More Details
12.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.8
vs History
30
vs Industry
12
Median 3Y
12.9
Median 5Y
-12.8
Industry
12.7
Forward
8.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.8
Median 5Y
-13.4
Industry
16.3
Forward
120.2
More Details
9.5
EV/OCF
EV/OCF
Enterprise Value to OCF
9.5
vs History
22
vs Industry
39
Median 3Y
5.7
Median 5Y
-6
Industry
15.1
More Details
11.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
11.6
vs History
22
vs Industry
29
Median 3Y
6.9
Median 5Y
-5.8
Industry
17.7
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
42
vs Industry
78
Median 3Y
0.5
Median 5Y
0.5
Industry
2
More Details

Multiples Across Competitors

SNDL Competitors Multiples
Sundial Growers Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Sundial Growers Inc
NASDAQ:SNDL
477.4m USD 0.7 -6.9 12.8 -51.8
US
Eli Lilly and Co
NYSE:LLY
929.3B USD 15.6 50.5 33.9 36.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
457.4B USD 5 18.2 15 19.4
CH
Roche Holding AG
SIX:ROG
227.4B CHF 3.7 24.1 11 12.4
UK
AstraZeneca PLC
LSE:AZN
207.3B GBP 4.7 29.1 108 158.1
CH
Novartis AG
SIX:NOVN
198B CHF 4.4 17.1 10.9 14
US
Merck & Co Inc
NYSE:MRK
222.5B USD 3.5 11.7 8.4 10
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.9 9.1 10.5
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
140.8B USD 2.2 14.3 7.3 10
P/E Multiple
Earnings Growth PEG
CA
Sundial Growers Inc
NASDAQ:SNDL
Average P/E: 22.2
Negative Multiple: -6.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.5
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.2
29%
0.6
CH
Roche Holding AG
SIX:ROG
24.1
29%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.1
18%
0.9
US
Merck & Co Inc
NYSE:MRK
11.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
7%
1.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.3
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Sundial Growers Inc
NASDAQ:SNDL
Average EV/EBITDA: 398.5
12.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.9
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15
8%
1.9
CH
Roche Holding AG
SIX:ROG
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
10.9
6%
1.8
US
Merck & Co Inc
NYSE:MRK
8.4
7%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
1%
7.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Sundial Growers Inc
NASDAQ:SNDL
Average EV/EBIT: 1 877.7
Negative Multiple: -51.8 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19.4
14%
1.4
CH
Roche Holding AG
SIX:ROG
12.4
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
158.1
22%
7.2
CH
Novartis AG
SIX:NOVN
14
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10
9%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
10%
1

See Also

Summary
SNDL intrinsic value, competitors valuation, and company profile.
DCF Valuation
SNDL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SNDL stock valuation using valuation multiples.
Wall Street Estimates
SNDL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SNDL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 295,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.